Tech Company Financing Transactions
SimBioSys Funding Round
SimBioSys secured a $15 million Series A funding round on 10/28/2021. Investors included Genoa Ventures, Northpond Ventures and AV8 Ventures.
Transaction Overview
Company Name
Announced On
10/28/2021
Transaction Type
Venture Equity
Amount
$15,000,000
Round
Series A
Investors
Genoa Ventures (Lead Investor) (Vikram Chaudhery)
Northpond Ventures (Lead Investor) (Andrea Jackson)
Proceeds Purpose
The new funding will allow SimBioSys to expand its state-of-the-art technology into other solid tumors beyond its current focus on breast cancer.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
180 N LaSalle St. 3250
Chicago, IL 60601
USA
Chicago, IL 60601
USA
Phone
Undisclosed
Website
Email Address
Overview
SimBioSys is a software company deploying a combination of biophysical modeling and artificial intelligence to revolutionize precision cancer care. Our portfolio of software applications enables individualized treatment planning, accelerated drug development, clinical trial optimization and comprehensive biomarker development.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Tushar Pandey
Chief Medical Officer
Anu Antony
Chief Scientific Officer
John Cole
Chief Technical Officer
Joseph Peterson
Vice President
Tricia Carrigan
VP - Bus. Development
Timothy Foley
VP - Regulatory Affairs
Eduardo Braun
Browse more venture capital transactions:
Prev: 10/28/2021: Immunefi venture capital transaction
Next: 10/28/2021: Selfbook venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. All VC database entries on this site are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs